Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
doi: 10.1074/jbc.270.25.15391 22 VrangNHansenMLarsenPJTang-ChristensenM
10.1016/j.mam.2012.10.010 Mol
GLP-1 agonists have well characterized side effects
While GLP-1 drugs are not yet FDA-approved specifically for alcohol use disorder, prescribers can discuss off-label use in appropriate clinical contexts
It is currently the subject of active Phase 3 clinical research, making it one of the most closely followed investigational peptides in the current pharmacological literature
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 23.80
US$ 27.50
US$ 22.99
